NovoTTF-100A

DEVICE3 trials

Sponsors

NovoCure Ltd., University of Florida

Conditions

Brain NeoplasmsGlioblastomaRecurrent Glioblastoma Multiforme

Phase 3

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

CompletedNCT00379470

NovoCure Ltd.Recurrent Glioblastoma Multiforme

Start: 2006-09-30End: 2011-01-31Updated: 2012-05-01

Phase 4

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

TerminatedNCT01756729

NovoCure Ltd.Recurrent Glioblastoma Multiforme

Start: 2012-12-31End: 2018-01-31Updated: 2016-03-02

Unknown Phase

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

TerminatedNCT01954576

University of FloridaBrain Neoplasms, Glioblastoma

Start: 2013-10-10End: 2021-05-14Updated: 2022-10-31

Related Papers

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.

2025-04-23

INNV-38. 3 DAYS-ON-1 DAY-OFF FRACTIONATED USE PROTOCOL FOR IMPROVED COMPLIANCE AND PREVENTATIVE SKIN SAFETY FOR USE OF TUMOR TREATING FIELDS: PRACTICE IMPROVEMENT STRATEGY IN NEURO-ONCOLOGY

Neuro-Oncology2024-11-011 citations

Tumor treating fields (TTFields) therapy skin safety and prevention strategy using a fractionated schema protocol (3-days on/1-day off), effect on skin adverse events.

Journal of Clinical Oncology2023-06-012 citations

Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study

Japanese Journal of Clinical Oncology2023-01-1621 citations

Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)

Discover Oncology2022-10-1414 citations

PATH-27. IDENTIFYING THE GENETIC SIGNATURE OF RESPONSE IN A PHASE II STUDY OF TUMOR TREATING FIELDS IN RECURRENT GLIOBLASTOMA

Neuro-Oncology2018-11-011 citations